Table 3 PDX host animal median survival.

From: Vertical pathway inhibition of receptor tyrosine kinases and BAD with synergistic efficacy in triple negative breast cancer

 

PDX

VEH

NCK

OSI

N + O

CRI

N + C

Median survival (Days)

USTC-0

25.5

42.0

34.0

67

34.5

74

USTC-1

22.5

34.5

29.5

41.5

27.0

43.5

  1. Median survival time of mice receiving NCK (NCK), Crizotinib (CRI), OSI-930 (OSI) or combinations in TNBC PDX USTC-0 or USTC-1.
Back to article page